(ENOV) Enovis - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1940145022

Stock: Orthopedic Bracing, Joint Implants, Recovery Devices, Surgical Tools

Total Rating 34

Risk 33

Buy Signal -0.43

Medical Devices +3.6
Health Care Equipment +4.8

Market Cap: 1,403m
Avg Trading Vol: 23.8M USD

ATR: 5.34%
Peers RS (IBD): 18.7

Risk 5d forecast
Volatility	52.5%
Relative Tail Risk	-8.31%

Reward TTM
Sharpe Ratio	-0.61
Alpha	-59.90

Character TTM
Beta	1.416
Beta Downside	1.848

Drawdowns 3y
Max DD	67.26%
CAGR/Max DD	-0.34

EPS (Earnings per Share)

EPS CAGR: 28.59%
EPS Trend: 73.2%

Last SUE: 4.00
Qual. Beats: 7

Revenue

Rev. CAGR: 12.08%
Rev. Trend: 96.2%

Last SUE: -1.20
Qual. Beats: 0

Risks

Technicals: choppy

Description: ENOV Enovis February 27, 2026

Enovis Corp (NYSE: ENOV) is a U.S.–based medical-technology firm that delivers clinically differentiated orthopedic and reconstructive solutions. It operates through two main divisions: the Prevention & Recovery segment, which supplies bracing, thermal therapy, bone-growth stimulators, compression garments and physical-therapy products to a broad range of clinicians; and the Reconstructive segment, which designs and sells surgical implants for hips, knees, shoulders, elbows, feet, ankles and fingers, as well as related productivity tools, under the ESAB and DJO brands.

In its most recent fiscal year (2025), Enovis reported revenue of roughly $2.1 billion, an 8 % year-over-year increase driven by strong demand for joint-replacement implants and a rebound in outpatient orthopedic procedures. The company posted an adjusted operating margin of 12 % and a backlog of $1.4 billion, indicating sustained order flow. Growth is underpinned by macro-level trends such as the aging U.S. population-projected to add 10 million adults over 65 by 2030-and a 5 % CAGR forecast for the global orthopedic device market through 2030, which benefits both its implant and therapy product lines.

For deeper quantitative insights, you may want to explore ValueRay’s analyst tools.

Headlines to watch out for

Orthopedic bracing demand drives Prevention and Recovery segment revenue
Elective joint replacement procedures boost Reconstructive segment sales
Healthcare spending trends impact medical device adoption
Regulatory approvals crucial for new product market entry
Supply chain disruptions affect manufacturing costs and product availability

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income: -1.18b TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.94 > 1.0
NWC/Revenue: 27.07% < 20% (prev 29.30%; Δ -2.22% < -1%)
CFO/TA 0.06 > 3% & CFO 217.3m > Net Income -1.18b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.02 > 1.5 & < 3
Outstanding Shares: last quarter (56.8m) vs 12m ago -2.70% < -2%
Gross Margin: 59.84% > 18% (prev 0.56%; Δ 5928 % > 0.5%)
Asset Turnover: 52.56% > 50% (prev 44.66%; Δ 7.90% > 0%)
Interest Coverage Ratio: -23.76 > 6 (EBITDA TTM -823.6m / Interest Expense TTM 46.8m)

Altman Z'' -2.65

A: 0.16 (Total Current Assets 1.21b - Total Current Liabilities 598.5m) / Total Assets 3.83b
B: -0.38 (Retained Earnings -1.47b / Total Assets 3.83b)
C: -0.26 (EBIT TTM -1.11b / Avg Total Assets 4.28b)
D: -0.67 (Book Value of Equity -1.56b / Total Liabilities 2.34b)
Altman-Z'' Score: -2.65 = D

Beneish M -3.51

DSRI: 1.02 (Receivables 442.8m/407.0m, Revenue 2.25b/2.11b)
GMI: 0.94 (GM 59.84% / 56.02%)
AQI: 0.81 (AQ_t 0.53 / AQ_t-1 0.66)
SGI: 1.07 (Revenue 2.25b / 2.11b)
TATA: -0.37 (NI -1.18b - CFO 217.3m) / TA 3.83b)
Beneish M-Score: -3.51 (Cap -4..+1) = AAA

What is the price of ENOV shares?

As of March 10, 2026, the stock is trading at USD 24.66 with a total of 1,230,816 shares traded.
Over the past week, the price has changed by -4.05%, over one month by +10.29%, over three months by -8.80% and over the past year by -30.55%.

Is ENOV a buy, sell or hold?

Enovis has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy ENOV.

StrongBuy: 7
Buy: 3
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ENOV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	45.2	83.2%
Analysts Target Price	45.2	83.2%

ENOV Fundamental Data Overview March 10, 2026

P/E Forward = 6.734
P/S = 0.6241
P/B = 0.9419
P/EG = 1.8989
Revenue TTM = 2.25b USD
EBIT TTM = -1.11b USD
EBITDA TTM = -823.6m USD
Long Term Debt = 1.26b USD (from longTermDebt, last quarter)
Short Term Debt = 59.7m USD (from shortTermDebt, last quarter)
Debt = 1.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.34b USD (from netDebt column, last quarter)
Enterprise Value = 2.75b USD (1.40b + Debt 1.38b - CCE 36.4m)
Interest Coverage Ratio = -23.76 (Ebit TTM -1.11b / Interest Expense TTM 46.8m)
EV/FCF = 137.9x (Enterprise Value 2.75b / FCF TTM 19.9m)
FCF Yield = 0.73% (FCF TTM 19.9m / Enterprise Value 2.75b)
FCF Margin = 0.89% (FCF TTM 19.9m / Revenue TTM 2.25b)
Net Margin = -52.69% (Net Income TTM -1.18b / Revenue TTM 2.25b)
Gross Margin = 59.84% ((Revenue TTM 2.25b - Cost of Revenue TTM 902.8m) / Revenue TTM)
Gross Margin QoQ = 60.69% (prev 59.92%)
Tobins Q-Ratio = 0.72 (Enterprise Value 2.75b / Total Assets 3.83b)
Interest Expense / Debt = 0.54% (Interest Expense 7.51m / Debt 1.38b)
Taxrate = 21.0% (US default 21%)
NOPAT = -879.0m (EBIT -1.11b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.02 (Total Current Assets 1.21b / Total Current Liabilities 598.5m)
Debt / Equity = 0.93 (Debt 1.38b / totalStockholderEquity, last quarter 1.49b)
Debt / EBITDA = -1.63 (negative EBITDA) (Net Debt 1.34b / EBITDA -823.6m)
Debt / FCF = 67.44 (Net Debt 1.34b / FCF TTM 19.9m)
Total Stockholder Equity = 2.18b (last 4 quarters mean from totalStockholderEquity)
RoA = -27.69% (Net Income -1.18b / Total Assets 3.83b)
RoE = -54.42% (Net Income TTM -1.18b / Total Stockholder Equity 2.18b)
RoCE = -32.36% (EBIT -1.11b / Capital Employed (Equity 2.18b + L.T.Debt 1.26b))
RoIC = -24.86% (negative operating profit) (NOPAT -879.0m / Invested Capital 3.54b)
WACC = 5.83% (E(1.40b)/V(2.78b) * Re(11.13%) + D(1.38b)/V(2.78b) * Rd(0.54%) * (1-Tc(0.21)))
Discount Rate = 11.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.99%
[DCF] Terminal Value 80.82% ; FCFF base≈19.9m ; Y1≈13.1m ; Y5≈5.97m
[DCF] Fair Price = N/A (negative equity: EV 190.1m - Net Debt 1.34b = -1.15b; debt exceeds intrinsic value)
EPS Correlation: 73.21 | EPS CAGR: 28.59% | SUE: 4.0 | # QB: 7
Revenue Correlation: 96.17 | Revenue CAGR: 12.08% | SUE: -1.20 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.89 | Chg7d=+0.052 | Chg30d=+0.052 | Revisions Net=+3 | Analysts=10
EPS current Year (2026-12-31): EPS=3.58 | Chg7d=+0.168 | Chg30d=+0.168 | Revisions Net=+8 | Growth EPS=+8.5% | Growth Revenue=+4.1%
EPS next Year (2027-12-31): EPS=3.94 | Chg7d=+0.108 | Chg30d=+0.108 | Revisions Net=+3 | Growth EPS=+10.1% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: +0.43 (5 Up / 2 Down within 30d for Next Quarter)

Additional Sources for ENOV Stock

Fund Manager Positions: Dataroma | Stockcircle